Discovery of BBI-355, a Potent, Selective, and Orally Available Checkpoint Kinase 1 Inhibitor for the Treatment of Extrachromosomal DNA Oncogene-Amplified Cancers

发表于 2026-7-17 09:21:45

期刊：Journal of Medicinal Chemistry

文献作者：S. Todd Meyer; Sudhir Chowdhry; Rachelle J. Elsdon; Jacques Mauger; Yen P. H. Truong; Ryan Hansen; Joshua Plum; Auzon Steffy; AnneMarie Pferdekamper; Benjamin Norman; Salvador Garcia; Edison Tse; Julius Apuy; Ardalan Ardeshiri; Shailaja Kasibhatla; Christian A. Hassig; Anthony B. Pinkerton

出版日期：--

DOI号：10.1021/acs.jmedchem.6c00822

下载链接：https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.6c00822

文献链接：https://doi.org/10.1021/acs.jmedchem.6c00822

当前文献来源于 American Chemical Society (ACS)。

备注信息：

发表于 2026-7-17 09:21:46

: 当前求助已完成，请重新发起求助。
已完结状态的附件将会在24小时内删除。

[ACS] Discovery of BBI-355, a Potent, Selective, and Orally Available Checkpoint Kinase 1 Inhibitor for the Treatment of Extrachromosomal DNA Oncogene-Amplified Cancers

已采纳

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[ACS] Discovery of BBI-355, a Potent, Selective, and Orally Available Checkpoint Kinase 1 Inhibitor for the Treatment of Extrachromosomal DNA Oncogene-Amplified Cancers 一键复制